Na-ekesa nnukwu lymphoma B-cell (DLBCL), NOS, GCB subtype, isi usoro ụjọ nke etiti lymphoma-01

Na Disemba 2019, Maazị Wang, onye nkuzi si Northeast China, malitere inwe isi ọwụwa. Na Disemba 19th, 2019, ule nyocha gosipụtara ihe ndị a: PET-CT gosipụtara njupụta njupụta nwere mmụba nke ukwuu FDG metabolism na mpaghara ihu ekpe na corpus callosum ikpere (ihe dịka 3.4 * 1.9 cm, SUVmax=34.4). Biopsy na immunohistochemistry kwadoro na-agbasa nnukwu lymphoma B-cell (DLBCL, NOS, GCB subtype), yana immunophenotype na-egosi Ki67 (50%+), CD19 (+), CD20 (+), PAX5 (+), CD79(+), MUM1(+), BCL(+), CD10(-/+), CD2(obere+). Nnyocha mmiri nke cerebrospinal kpughere 6% mkpụrụ ndụ lymphoid akabeghị aka nwere mgbanwe mgbanwe. Nchoputa a bu lymphoma sistemu akwara etiti (DLBCL, subtype GCB).

Mgbe nyochachara nhọrọ ọgwụgwọ n'ịntanetị, Maazị Wang mụtara maka ikike immunotherapy nke ụlọ ọgwụ Lu Dao Pei wee chọọ ọkachamara ha ozugbo. N'ịgbaso nyocha anụ ahụ nke ọma na nyocha nke ọma site n'aka ndị ọkachamara ụlọ ọgwụ, e kpebiri na Maazị Wang ga-esonye na nnwale ụlọ ọgwụ maka ọgwụgwọ CART, kpọmkwem na-eji sel CD19 CART. Ọ natara infusion cell CD19 CAR-T autologous na Eprel 24, 2023. Ka ọ na-erule Julaị 30, 2023, a nyochara na ọ nwetagoro mgbaghara zuru oke (CR) wee laghachitela ndụ nkịtị.